Non-coding RNAs for medical practice in oncology

Tetsuro Setoyama1, Hui Ling, Shoji Natsugoe

  • 1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Insights

Alterations in non-coding RNAs (ncRNAs), including microRNAs (miRNAs), drive cancer development and metastasis. Profiling these ncRNAs offers new diagnostic markers and RNA-based cancer therapies.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), play crucial roles in human cancer, influencing initiation, progression, and metastasis.
  • Differential expression of ncRNAs in cancer cells stems from genomic locations, epigenetic modifications, and altered processing machinery.
  • These molecular alterations impact numerous target protein-coding genes, contributing to the malignant phenotype.

Purpose of the Study:

  • To explore the involvement of ncRNAs in cancer development and metastasis.
  • To investigate the potential of ncRNA expression profiling for cancer diagnosis, staging, prognosis, and treatment response.
  • To identify novel ncRNAs as potential cancer-predisposing genes and therapeutic targets.

Main Methods:

  • Expression profiling of human tumors using miRNA and other ncRNA data.
  • Analysis of genomic regions, epigenetic mechanisms, and RNA processing machinery in cancer cells.
  • Identification of ncRNAs targeting protein-coding genes or acting as downstream targets of oncogenic pathways.

Main Results:

  • ncRNA expression signatures are associated with cancer diagnosis, staging, progression, prognosis, and treatment response.
  • ncRNAs, including miRNAs and non-coding ultraconserved genes, are implicated as cancer-predisposing genes.
  • ncRNAs are involved in the complex genetic landscape of cancer, contributing to the malignant phenotype.

Conclusions:

  • ncRNA alterations are fundamental to human cancer pathogenesis.
  • ncRNA expression profiling provides valuable biomarkers for cancer management.
  • ncRNAs hold significant promise for the development of novel, RNA-based cancer therapies.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...